Global pharma looks to India: Prospects for growth

En este entorno de nuevos desafíos, la industria farmacéutica se está reinventado a través de la búsqueda de nuevas formas de aumentar los ingresos y el potencial de investigación, gestionar los riesgos, reducir los tiempos a la hora de introducir los productos en el mercado y recortar los costes a lo largo de la cadena de valor. En este sentido, India comienza a despuntar y es probable que se convierta en un competidor global en determinadas áreas y un socio potencial en otras.

Pharma 2020: Taxing times ahead - Which path will you take?

The global financial crisis, government pressure, changing market dynamics for an industry experiencing significant change and rapidly evolving healthcare reforms are likely to drive up the effective tax rate for the pharmaceutical and life sciences industry, according to a report by PricewaterhouseCoopers (PwC) entitled Pharma 2020: Taxing times ahead - Which path will you take?. The industry’s response to these trends, including diminishing reliance on the 'blockbuster drug model', will make tax planning more complicated and challenging for tax executives working for pharmaceutical and life sciences companies.

Pharma 2020: Marketing the future

The current role of the pharmaceutical industry’s sales and marketing workforce will be replaced by a new model over the next ten years as the industry shifts from a mass-market to a target-market approach to increase revenue, according to a new report published by PricewaterhouseCoopers (PwC)